Research Center Uganda
Conducting clinical research to address health issues in African region

- Located within Mbarara University of Science and Technology (MUST) and Mbarara Regional Referral Hospital (MRRH).
- Activity initiated in 1996 in Mbarara, Southwestern Uganda
- Site for high-profile multi-centric trials for over 20 years
- An experienced team of over 100 medical doctors, epidemiologists, statisticians, biologists, lab technologists, IT and data managers, research quality officers, nurses...
- Laboratory: Accreditation GCLP (Good Clinical Laboratory Practice) and biosafety level 3; equipped for microbiology, biochemistry, hematology and molecular biology tests (classical PCR, real-time qPCR, Genexpert, PCR test for SARS-CoV).
- Expertise on several infectious diseases: malaria, Ebola, yellow fever, tuberculosis, central nervous system infections.
- In close collaboration with MSF

IMPROVING ACCESS TO CARE AND HEALTH FOR THE MOST VULNERABLE POPULATIONS

Our competencies

Research unit
- Medical,
- Data management & IT
- Monitoring and Quality Control

Laboratory unit
- Biologists (quality management, biosafety)
- Lab technologists and technicians

Support unit
- Administrative, human resources, finance, logistics

Building capacities in the country and regional integration

- Long term investment in the country and contributing to improve research and healthcare
- Qualified local investigators with experience in prevailing health conditions eg TB
- Clinical trials module of MPH and Bachelor of Lab Science at MUST
- Laboratory support for MDR-TB activities, COVID-19
- Development of Research Guidelines and tools (Post-trial access guidelines, Community engagement guidelines)

2007-2010
AQUAMAT: Evidence of significant reduction in mortality with artesunate in African children with severe malaria.

2019-2022
Site for the RIFASHORT study which investigated benefit of increasing Rifampicin dose in shortening treatment duration for Tuberculosis.

2019-2023
Demonstration of the feasibility of using fractional doses of yellow fever vaccine in adult, children and HIV infected adults.

2022-2023
MSF Ebola outbreak supported

2018-2023
Participation in the EDCTP-funded DNDI trial that evaluates efficacy and safety of fexinidazole in patients with Trypanosoma brucei rhodesiense (r-THA).

2019
Evaluation of 4-in-1 treatment, a combination of 4 drugs in a single, easy-to-use, heat-stable, tasteless, solid capsule for children with HIV in Uganda.

2019-2022
Site for studies in the TB-speed project, which aims to reduce mortality by improving tuberculosis diagnosis in children.

2019-2022
ZEBOVAC: Evaluation of the safety and immunogenicity of the Ebola vaccination schedule of the Ad26.ZEBOV/MVA-BN®-Filo vaccine

2023-2024
Site for DATURA which is investigating the impact of intensifying the initial TB treatment phase on mortality

2023-2025
TB-Algo Evaluation of the effectiveness and acceptability of two treatment decision algorithms for TB in children